Theolytics

All Events Fund articles Fund PR Portfolio articles Portfolio PR

Maximizing value when developing oncolytic viral therapy

2025.04.012025.04.30 / As the new CEO for Theolytics, David Apelian aims to take full advantage of the first clinical studies for the company’s lead product. The UK-based biotech has a whole potential platform for creating ...

Theolytics Appoints David Apelian MD, PhD, MBA as CEO

2024.12.172025.04.30 / David Apelian MD PhD MBA, an experienced CEO with significant development and regulatory experience in virology and immune-oncology joins Theolytics Dr Apelian joins as the company advances its f ...

Theolytics Doses First Patient in Phase I/IIa Trial of THEO-260 in Ovarian Cancer

2024.11.192025.04.30 / THEO-260 lyses cancer cells and cancer associated fibroblasts whilst alleviating immune suppression in preclinical studies. THEO-260 is a mechanistically novel oncolytic immunotherapy developed to ...

Evolving to the next phase of viral therapy development

2024.05.012024.05.13 / UK-based Theolytics is about to begin the first clinical trials for one of its cancer-fighting viruses. It’s a major step for any biotech company, often reached only after years of adjusting and read ...

Sound Bioventures joins £19M ($24.5M) financing in UK oncolytic virus company Theolytics

2024.04.172024.05.13 / Sound Bioventures joins strong international syndicate comprising M Ventures, Taiho Ventures, Epidarex Capital, Oxford Science Enterprises and the University of Oxford New funding enables Theolyt ...